Overview

PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
This study will compare the efficacy of PS-341 versus high dose dexamethasone.
Phase:
Phase 3
Details
Lead Sponsor:
Millennium Pharmaceuticals, Inc.
Treatments:
BB 1101
Bortezomib
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate